FBLG
FibroBiologics, Inc.0.2408
-0.0222-8.44%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
18.08MP/E (TTM)
-Basic EPS (TTM)
-0.48Dividend Yield
0%Recent Filings
10-K
FY2025 results
FibroBiologics posted FY2025 results for the fiscal year ended December 31, 2025, as an emerging growth biotech with no revenue disclosed in the 10-K, focused on fibroblast therapies for wounds, MS, and degenerative disc disease. Lacking quarterly breakdowns or financial statements in the filing, key momentum shows preclinical completion for CYWC628 wound healing, paving for a Phase 1/2 trial in Australia Q1 2026, alongside plans for CYMS101 MS IND in H1 2026. No debt, capex, or cash flow details provided. Pipeline advances steadily. Clinical delays could stall momentum.
8-K
Stockholders approve reverse split, warrants
FibroBiologics stockholders overwhelmingly approved a reverse stock split at a ratio of 1-for-5 to 1-for-30, set by the Board before February 20, 2027, at their Special Meeting on February 20, 2026, with 53.6M for versus 1.3M against. They also ratified issuance of up to 22.5M common shares upon warrant exercises tied to November and December 2025 financings, satisfying Nasdaq rules. Stockholders approved all five proposals.
8-K
Nasdaq delisting risk escalates
FibroBiologics received Nasdaq notice on February 3, 2026, citing persistent MVLS below $35M—adding to its bid price woes—as grounds for delisting. The company awaits a hearings panel decision after pitching its compliance plan. It filed for a 1-for-5 to 1-for-30 reverse split on December 29, 2025. No guarantees success.
8-K
Nasdaq delisting notice issued
FibroBiologics faces Nasdaq delisting after its stock bid price stayed below $1.00 for 30 days through December 29, 2025, breaching Listing Rule 5550(a)(2). The company plans to appeal to the Hearings Panel, which stays action pending outcome, while pushing a 1-for-5 to 1-for-30 reverse split via proxy vote filed December 29. No guarantees success will cure noncompliance.
IPO
Employees
Sector
Industry
AIBT
Aibotics Inc.
0.00+0.00
CERO
CERo Therapeutics Holdings, Inc
0.09-0.01
CMMB
Chemomab Therapeutics Ltd.
2.06+0.00
ETNB
89bio, Inc.
14.84+0.00
FBRX
Forte Biosciences, Inc.
23.27+1.31
FGEN
FibroGen, Inc
9.51-0.53
IMA
ImageneBio, Inc.
6.25+0.08
LGVN
Longeveron Inc.
0.55+0.00
RMTG
Regenerative Medical Technology
0.04+0.00
YDES
YD Bio Limited
12.62+0.22